Affordable Access

deepdyve-link
Publisher Website

Comparison of transcatheter versus surgical aortic valve implantation in high-risk patients: A nationwide study in France.

Authors
  • Armoiry, Xavier1
  • Obadia, Jean-François2
  • Pascal, Léa3
  • Polazzi, Stéphanie4
  • Duclos, Antoine5
  • 1 Division of Health Sciences, Warwick Medical School, University of Warwick, Coventry, England; Hospices Civils de Lyon/Quai des Célestins, Lyon, France; UMR-CNRS 5510/MATEIS, Lyon, France. Electronic address: [email protected] , (France)
  • 2 Service de Chirurgie Cardio-thoracique et Transplantation, Hôpital Cardio-thoracique Louis Pradel, Lyon-Bron, Bron, France. , (France)
  • 3 Hospices Civils de Lyon, Pôle de Santé Publique, Service des Données de Santé, Lyon, France. , (France)
  • 4 Hospices Civils de Lyon, Pôle de Santé Publique, Service des Données de Santé, Lyon, France; Université Claude Bernard Lyon 1, Health Services and Performance Research lab (HESPER EA7425), F-69008, Lyon, France. , (France)
  • 5 Hospices Civils de Lyon, Pôle de Santé Publique, Service des Données de Santé, Lyon, France; Université Claude Bernard Lyon 1, Health Services and Performance Research lab (HESPER EA7425), F-69008, Lyon, France; Center for Surgery and Public Health, Brigham and Women's Hospital, Harvard Medical School, Boston, Mass. , (France)
Type
Published Article
Journal
The Journal of thoracic and cardiovascular surgery
Publication Date
Sep 01, 2018
Volume
156
Issue
3
Identifiers
DOI: 10.1016/j.jtcvs.2018.02.092
PMID: 29764686
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

To compare the clinical outcomes and direct costs at 5 years between transcatheter aortic valve implantation (TAVI) and surgical aortic valve replacement (SAVR) using real-world evidence. We performed a nationwide longitudinal study using data from the French Hospital Information System from 2009 to 2015. We matched, inside hospitals, 2 cohorts of adults who underwent TAVI or SAVR during 2010 on propensity score based on patient characteristics. Outcomes analysis included mortality, morbidity, and total costs and with a maximum 60-month follow-up. Clinical outcomes were compared between cohorts using hazard ratios (HRs) estimated from a Cox proportional hazards model for all-cause death, and from Fine and Gray's competing risk model for morbidity. Based on a cohort of 1598 patients (799 in each group) from 27 centers, a higher risk of death was observed after 1 year with TAVI compared with SAVR (16.8% vs 12.8%, respectively; HR, 1.33; 95% confidence interval [CI], 1.02-1.72) and was sustained up to 5 years (52.4% vs 37.2%; HR, 1.56; 95% CI, 1.33-1.84). At 5 years, the risk of stroke was increased (HR, 1.64; 95% CI, 1.07-2.54) as was myocardial infarction (HR, 2.30; 95% CI, 1.12-4.69) and pacemaker implantation (HR, 2.40; 95% CI, 1.81-3.17) after TAVI. The hospitalization costs per patient at 5 years were €69,083 after TAVI and €55,687 after SAVR (P < .001). In our study, high-risk patients harbored a greater risk of mortality and morbidity at 5 years after TAVI compared with those who underwent SAVR and higher hospitalizations costs. Those results should encourage caution before expanding the indications of TAVI. Copyright © 2018 The American Association for Thoracic Surgery. Published by Elsevier Inc. All rights reserved.

Report this publication

Statistics

Seen <100 times